CUV · ASX

Clinuvel Pharmaceuticals Limited (ASX:CUV)

AU$11.79

 -0.15 (-1.256%)
ASX:Live
20/12/2024 04:10:10 PM
Near Support Near 52 Week Low HALO Value HALO Small HALO Ords +7
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CUV Overview

CUV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Very Weak

Halo Model

MQV

Weak

GARP

Weak

MQV Small

Weak

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Weak

Growth

Earnings

Neutral

Dividends

Strong

Quality

Capital Efficiency

Weak

Balance Sheet

Very Weak

About CUV

Website

Clinuvel Pharmaceuticals Limited

Telephone

61.3.9660.4900

Address

Level 11 535 Bourke Street Melbourne, Victoria (VIC) 3000

Description

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

CUV Price Chart

Key Stats

Market Cap

AU$600.73M

PE

21.10

EV/EBITDA

11.8

Dividends Overview

DIV Yield

.5%

Franking

100%

Ex Dividend Date (est.)

05-Sep-24

Market Data

52 weeks range

Low 11.76 - 17.71

Trade Value (12mth)

AU$355,668.00

1 week

-1.57%

1 month

-10.9%

YTD

-26.57%

1 year

-27.28%

All time high

45.88

Key Fundamentals

EPS 3 yr Growth

42.90%

EBITDA Margin

50.70%

Operating Cashflow

$37m

Free Cash Flow Return

20.10%

ROIC

19.30%

Interest Coverage

1,076.40

Quick Ratio

8.40

Other Data

Shares on Issue (Fully Dilluted)

51m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

05-Sep-24

Next Dividend Pay Date (est.)

20-Sep-24

Reporting Currency

AUD

Short Sell (% of issue)

6.72

CUV Announcements

Latest Announcements

Date Announcements

18 December 24

Revised Securities Trading Policy

×

Revised Securities Trading Policy

06 December 24

Becoming a substantial holder

×

Becoming a substantial holder

05 December 24

Chair's letter to Shareholders

×

Chair's letter to Shareholders

04 December 24

Notification of cessation of securities - CUV

×

Notification of cessation of securities - CUV

20 November 24

SCENESSE dosage expansion under review by EMA

×

SCENESSE dosage expansion under review by EMA

18 November 24

CLINUVEL prioritises three strategic programs

×

CLINUVEL prioritises three strategic programs

18 November 24

CLINUVEL Bell Potter Healthcare Conference Presentation

×

CLINUVEL Bell Potter Healthcare Conference Presentation

17 October 24

Final Director's Interest Notice - Brenda Shanahan

×

Final Director's Interest Notice - Brenda Shanahan

16 October 24

Chair's Address

×

Chair's Address

16 October 24

Managing Director Presentation

×

Managing Director Presentation

16 October 24

Results of Meeting

×

Results of Meeting

03 October 24

Appendix 3Y - Karen Agersborg

×

Appendix 3Y - Karen Agersborg

02 October 24

Notification of cessation of securities - CUV

×

Notification of cessation of securities - CUV

01 October 24

Canadian New Drug Submission for SCENESSE in EPP filed

×

Canadian New Drug Submission for SCENESSE in EPP filed

27 September 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

26 September 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

20 September 24

SCENESSE data to be presented at global porphyria conference

×

SCENESSE data to be presented at global porphyria conference

19 September 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

13 September 24

Change of AGM Time of Meeting

×

Change of AGM Time of Meeting

13 September 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

10 September 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

10 September 24

Initial Director's Interest Notice - Matthew Pringle

×

Initial Director's Interest Notice - Matthew Pringle

10 September 24

Initial Director's Interest Notice - Guy van Dievoet

×

Initial Director's Interest Notice - Guy van Dievoet

10 September 24

Initial Director's Interest Notice - Pearl Grimes

×

Initial Director's Interest Notice - Pearl Grimes

09 September 24

Chair's letter to Shareholders

×

Chair's letter to Shareholders

CUV Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock 0.42 0.62 0.72 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock 0.40 0.59 0.70 Lock Lock Lock
     Growth % Lock Lock Lock Lock -15.6 46.6 15.5 Lock Lock Lock
     PE X Lock Lock Lock Lock 42.7 34.6 21.1 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 24.7 21.7 11.8 Lock Lock Lock
CFPS $ Lock Lock Lock Lock 0.69 0.81 0.87 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.74 0.65 0.57 Lock Lock Lock
     Growth % Lock Lock Lock Lock 10.8 18.1 6.9 Lock Lock Lock
     Yield % Lock Lock Lock Lock 5.0 3.7 3.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.04 0.05 0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock 60.0 25.0 0.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.1 0.3 0.5 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 9 8 7 Lock Lock Lock
BPS $ Lock Lock Lock Lock 2.54 3.33 4.05 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 2.54 3.33 4.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.2 31.2 21.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 52 52 51 Lock Lock Lock
Basic m Lock Lock Lock Lock 49 49 50 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 66 78 88 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37.0 19.2 12.6 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 14 10 14 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 47 51 58 Lock Lock Lock
     Growth % Lock Lock Lock Lock 32.4 8.5 14.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 70.9 64.6 65.7 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 29 35 34 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock 34 42 45 Lock Lock Lock
     Growth % Lock Lock Lock Lock 22.8 23.2 7.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock 51.5 53.2 50.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock 33 41 44 Lock Lock Lock
     Growth % Lock Lock Lock Lock 23.9 23.7 6.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock 50.3 52.2 49.4 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock 34 46 51 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 13 15 15 Lock Lock Lock
Net Income $m Lock Lock Lock Lock 21 31 36 Lock Lock Lock
     Growth % Lock Lock Lock Lock -15.6 46.6 16.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock 31.8 39.1 40.4 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 40 37 37 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 6 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 -29 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -2 -2 -4 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 39 36 31 Lock Lock Lock
     Growth % Lock Lock Lock Lock 114.2 -9.0 -12.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.6 0.5 0.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 122 157 184 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 145 195 232 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -120 -156 -183 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 19 30 29 Lock Lock Lock
Equity $m Lock Lock Lock Lock 126 165 203 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 127 165 204 Lock Lock Lock
     Growth % Lock Lock Lock Lock 26.8 30.7 23.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock 14.4 15.7 15.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 16.6 18.6 17.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock 29.2 28.0 23.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock 18.5 21.0 19.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 35.2 25.3 20.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A 1,076.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -3.6 -3.7 -4.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -95.8 -94.6 -90.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 10.2 7.4 8.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 10.1 7.1 8.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.4 82.7 82.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 290.4 144.8 147.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.1 4.1 3.6 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 7.6 4.9 3.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.5 0.5 0.4 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.4 3.6 2.7 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.5 0.4 0.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.5 0.4 0.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 52.2 58.2 57.5 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 23.7 23.4 21.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 39.2 32.9 29.7 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock 14.4 15.7 15.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 16.6 18.6 17.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 90.5 91.9 93.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 15.1 17.1 16.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 47.9 74.7 121.5 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 89.7 89.5 100.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 137.6 164.2 221.8 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 26.6 15.7 29.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 111.1 148.5 191.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

05-Sep-24

DIV Yield

.5%

Franking Level

100%

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

6.72%

Value ($M)

41

Prior Change

0.10%

7 Day Change

0.10%

1 Month Change

0.60%

3 Month Change

1.00%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CUV Shortsell

Frequently Asked Questions

The current share price of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$11.79.
The 52-week high share price for Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$17.71.
The 52-week low share price for Clinuvel Pharmaceuticals Limited (CUV:ASX)? is AU$11.76.
The current TTM dividend payout for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 0.50.
The last dividend payment of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$0.05.
Clinuvel Pharmaceuticals Limited (CUV:ASX) has a franking level of 100.0%.
Clinuvel Pharmaceuticals Limited (CUV:ASX) is classified in the Healthcare.
The current P/E ratio for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 21.10.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.